Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 2/3 1Phase 1 1

Status

Recruiting 5Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 8Observational 2

Sponsor

Conditions

Breast Neoplasms 10163Neoplasms 7801Carcinoma, Non-Small-Cell Lung 5744Prostatic Neoplasms 5016Colorectal Neoplasms 4588Lung Neoplasms 3716Leukemia, Myeloid, Acute 3097Neoplasm Metastasis 3074Multiple Myeloma 3073Pancreatic Neoplasms 2837Melanoma 2646Lymphoma 2569Ovarian Neoplasms 2565Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Recurrence 2221Head and Neck Neoplasms 2095Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia 2011Brain Neoplasms 1899Glioblastoma 1791Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1714Uterine Cervical Neoplasms 1684Lymphoma, Follicular 1651Squamous Cell Carcinoma of Head and Neck 1649Lymphoma, Large B-Cell, Diffuse 1596Carcinoma, Renal Cell 1574

Interventions

Sorafenib 2nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Interventional × HCC × Clear all
NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting
40 enrolled

HCC

NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting
300 enrolled

HCC

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting
44 enrolled

HCC

NCT06766773 2025-01-10

CWSRIH-HCC

The First People's Hospital of Neijiang

Phase NA Active not recruiting
80 enrolled

HCC

NCT06463444 2024-06-17

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Tongji Hospital

Phase 1 Recruiting
30 enrolled

HCC

NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
30 enrolled

HCC

NCT04123340 2023-01-06

IAMCOMPLETE

Leiden University Medical Center

Phase 2 Completed
20 enrolled

HCC

NCT01470495 2017-03-28

REPEAT

Southwest Hospital, China

Phase NA Unknown
430 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡